The estimated Net Worth of Richard T Kenney is at least 40.8 千$ dollars as of 9 June 2021. Dr Kenney owns over 15,000 units of Sonnet BioTherapeutics Inc stock worth over 40,765$ and over the last 9 years he sold SONN stock worth over 0$.
Dr has made over 2 trades of the Sonnet BioTherapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of SONN stock worth 23,100$ on 9 June 2021.
The largest trade he's ever made was buying 15,000 units of Sonnet BioTherapeutics Inc stock on 9 June 2021 worth over 23,100$. On average, Dr trades about 3,571 units every 3 days since 2015. As of 9 June 2021 he still owns at least 50,000 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Dr Kenney stock trades at the bottom of the page.
Dr. Richard T. Kenney is the Chief Medical Officer at Sonnet BioTherapeutics Inc.
Dr Kenney is 62, he's been the Chief Medical Officer of Sonnet BioTherapeutics Inc since . There are 3 older and 3 younger executives at Sonnet BioTherapeutics Inc. The oldest executive at Sonnet BioTherapeutics Holdings Inc is Dr. John K. Cini Ph.D., 68, who is the Chief Scientific Officer & Co-Founder.
Richard's mailing address filed with the SEC is 1616 Eastlake Ave E #310, Seattle, WA 98102, USA.
Over the last 7 years, insiders at Sonnet BioTherapeutics Inc have traded over 53,380$ worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth 290,512$ . The most active insiders traders include Pankaj Mohan、Donald J. Griffith、Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of 21,474$. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth 12,739$.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: